Recent News

• 10.28.2026 - LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
• 10.22.2026 - LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
• 08.11.2026 - LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
• 08.04.2026 - LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
• 07.06.2026 - LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
• 06.24.2026 - LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
• 06.07.2026 - LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
• 05.26.2026 - LENZ Therapeutics to Participate in Upcoming Investor Conferences
• 05.11.2026 - LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
• 05.04.2026 - LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

Recent Filings

• 10.28.2026 - 8-K Current report
• 10.28.2026 - EX-99.1 EX-99.1
• 10.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2026 - 8-K Current report
• 08.11.2026 - EX-99.1 EX-99.1
• 07.02.2026 - 8-K Current report
• 06.26.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors